Clinical trial • Phase III • Oncology
NIVOLUMAB for Advanced renal cell carcinoma
Phase III trial of NIVOLUMAB for Advanced renal cell carcinoma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced renal cell carcinoma
- Trial Stage
- Phase III
- Drug Modality
- Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 15-12-2023
- First CTIS Authorization Date
- 30-01-2024
Trial design
Randomised, nivolumab combined with ipilimumab versus nivolumab and placebo (placebo: 5% dextrose or sodium chloride solution as listed).-controlled Phase III trial in Austria, Czechia, Greece and others.
- Randomised
- Yes
- Comparator
- Nivolumab combined with Ipilimumab versus Nivolumab and placebo (placebo: 5% Dextrose or Sodium chloride solution as listed).
- Target Sample Size
- 194
Eligibility
Recruits 194 Vulnerable population selected (isVulnerablePopulationSelected = true). Subject information sheets and informed consent forms (L1 documents) are present for multiple Member States (see document listings per country). No explicit wording on assent or parental consent for minors was found in the available data..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true). Subject information sheets and informed consent forms (L1 documents) are present for multiple Member States (see document listings per country). No explicit wording on assent or parental consent for minors was found in the available data.
Inclusion criteria
- {"criterion_text":"- Histological confirmation of renal carcinoma with clear cell component including participants who may have sarcomatoid features.\n- Advanced (not amenable to curative surgery or radiation therapy) renal cell carcinoma (RCC) or metastatic RCC (mRCC).\n- Measurable disease by CT or MRI per RECIST 1.1 criteria.\n- No prior systemic therapy for RCC\n- Must be intermediate or poor risk as per International Metastatic RCC Database Consortium (IMDC)."}
Exclusion criteria
- {"criterion_text":"- Any active central nervous system (CNS) metastases.\n- Active, known, or suspected autoimmune disease\n- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA-4 antibody, or any other agents specifically targeting T-cell co stimulation or checkpoint pathways"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Progression free survival (PFS) by BICR","definition_or_measurement_approach":"PFS assessed by Blinded Independent Central Review (BICR); main objectives reference RECIST 1.1 for assessment."}
- {"endpoint_text":"- Overall Response Rate (ORR) by BICR","definition_or_measurement_approach":"ORR assessed by Blinded Independent Central Review (BICR) using RECIST 1.1 as indicated in main objectives."}
Secondary endpoints
- {"endpoint_text":"- Overall survival (OS)","definition_or_measurement_approach":"OS (as listed); no further measurement definition provided in the available data."}
- {"endpoint_text":"- Overall response rate (ORR) by Investigator","definition_or_measurement_approach":"ORR assessed by Investigator (per endpoint text)."}
- {"endpoint_text":"- Disease control rate (DCR) by Investigator and by blinded independent central review (BICR)","definition_or_measurement_approach":"DCR assessed by Investigator and by BICR (per endpoint text)."}
- {"endpoint_text":"- Duration of response (DoR) by Investigator and by blinded independent central review (BICR)","definition_or_measurement_approach":"DoR assessed by Investigator and by BICR (per endpoint text)."}
- {"endpoint_text":"- Time to objective response (TTR) by Investigator and by blinded independent central review (BICR)","definition_or_measurement_approach":"TTR assessed by Investigator and by BICR (per endpoint text)."}
- {"endpoint_text":"- Progression free survival (PFS) and PFS2 per Investigator","definition_or_measurement_approach":"PFS and PFS2 assessed by Investigator (per endpoint text)."}
- {"endpoint_text":"- Incidence of adverse events (AEs), Serious Adverse Events, drug - related SAEs and significant changes in laboratory tests (Hematology tests, Coagulation tests), Clinical Chemistry Tests and Serology Tests)","definition_or_measurement_approach":"Safety endpoints based on incidence/reporting of AEs, SAEs, drug-related SAEs and significant laboratory changes (per endpoint text)."}
- {"endpoint_text":"- PFS, ORR and OS based on GEP signatures","definition_or_measurement_approach":"Efficacy endpoints (PFS, ORR, OS) evaluated by gene expression profile (GEP) signatures (per endpoint text)."}
- {"endpoint_text":"- Overall Survival based on programmed cell death protein ligand-1 (PD-L1) expression","definition_or_measurement_approach":"OS stratified/analysed by PD-L1 expression (per endpoint text)."}
- {"endpoint_text":"- Overall response rate (ORR) by BICR based on PD-L1 expression","definition_or_measurement_approach":"ORR by BICR analysed by PD-L1 expression (per endpoint text)."}
- {"endpoint_text":"- Progression Free Survival (PFS) by BICR based on PD-L1 expression)","definition_or_measurement_approach":"PFS by BICR analysed by PD-L1 expression (per endpoint text)."}
Recruitment
- Planned Sample Size
- 194
- Recruitment Window Months
- 92
- Consent Approach
- Subject information sheets and informed consent forms (L1 documents) are provided per Member State (document titles indicate availability in Czech, Greek, Italian, Romanian, Spanish, French, Polish and English). Consent is provided by adult participants (documents labelled 'Main adult' exist); no explicit assent or parental consent text for minors was found in the available records.
Geography
- Total Number Of Sites
- 44
- Total Number Of Participants
- 194
Austria
- Latest Decision Or Authorization Date
- 02-03-2026
- Number Of Sites
- 2
- Number Of Participants
- 13
Sites
- Site Name
- Medical University Of Graz
- Department Name
- University clinic for Internal Medicine (UKIM)
- Principal Investigator Name
- Thomas Bauernhofer
- Principal Investigator Email
- thomas.bauernhofer@medunigraz.at
- Contact Person Name
- Thomas Bauernhofer
- Contact Person Email
- thomas.bauernhofer@medunigraz.at
- Site Name
- Medical University of Vienna
- Department Name
- Internal Medicine I - Department for Oncology
- Principal Investigator Name
- Manuela Schmidinger
- Principal Investigator Email
- manuela.schmidinger@meduniwien.ac.at
- Contact Person Name
- Manuela Schmidinger
- Contact Person Email
- manuela.schmidinger@meduniwien.ac.at
Czechia
- Latest Decision Or Authorization Date
- 02-03-2026
- Number Of Sites
- 3
- Number Of Participants
- 21
Sites
- Site Name
- Masarykuv Onkologicky Ustav
- Department Name
- Klinika komplexni onkologicke pece
- Principal Investigator Name
- Alexandr Poprach
- Principal Investigator Email
- poprach@mou.cz
- Contact Person Name
- Alexandr Poprach
- Contact Person Email
- poprach@mou.cz
- Site Name
- Fakultni Nemocnice Kralovske Vinohrady
- Department Name
- Onkologicka klinika
- Principal Investigator Name
- Jan Dvorak
- Principal Investigator Email
- jan.dvorak@fnkv.cz
- Contact Person Name
- Jan Dvorak
- Contact Person Email
- jan.dvorak@fnkv.cz
- Site Name
- Fakultni Thomayerova nemocnice
- Department Name
- Onkologicka klinika1. LF UK a FTN
- Principal Investigator Name
- Tomas Buchler
- Principal Investigator Email
- tomas.buchler@ftn.cz
- Contact Person Name
- Tomas Buchler
- Contact Person Email
- tomas.buchler@ftn.cz
Greece
- Latest Decision Or Authorization Date
- 02-03-2026
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- General University Hospital Of Larissa
- Department Name
- Department of Medical Oncology
- Principal Investigator Name
- Athanasios Kotsakis
- Principal Investigator Email
- thankotsakis@hotmail.com
- Contact Person Name
- Athanasios Kotsakis
- Contact Person Email
- thankotsakis@hotmail.com
- Site Name
- Athens Medical Center S.A.
- Department Name
- Department of Medical Oncology
- Principal Investigator Name
- Marinos Tsiatas
- Principal Investigator Email
- mtsiatas@otenet.gr
- Contact Person Name
- Marinos Tsiatas
- Contact Person Email
- mtsiatas@otenet.gr
Italy
- Latest Decision Or Authorization Date
- 08-04-2026
- Number Of Sites
- 4
- Number Of Participants
- 11
Sites
- Site Name
- Azienda USL Toscana Sud Est
- Department Name
- Oncology
- Principal Investigator Name
- Alketa Hamzaj
- Principal Investigator Email
- alketa.hamzaj@uslsudest.toscana.it
- Contact Person Name
- Alketa Hamzaj
- Contact Person Email
- alketa.hamzaj@uslsudest.toscana.it
- Site Name
- Azienda Ospedaliero Universitaria Parma
- Department Name
- Oncology
- Principal Investigator Name
- Sebastiano Buti
- Principal Investigator Email
- sebabuti@libero.it
- Contact Person Name
- Sebastiano Buti
- Contact Person Email
- sebabuti@libero.it
- Site Name
- European Institute Of Oncology S.r.l.
- Department Name
- Oncology
- Principal Investigator Name
- Franco Nolè
- Principal Investigator Email
- franco.nole@ieo.it
- Contact Person Name
- Franco Nolè
- Contact Person Email
- franco.nole@ieo.it
- Site Name
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
- Department Name
- Oncology Division
- Principal Investigator Name
- Francesca Valcamonico
- Principal Investigator Email
- franzval@yahoo.it
- Contact Person Name
- Francesca Valcamonico
- Contact Person Email
- franzval@yahoo.it
Romania
- Latest Decision Or Authorization Date
- 14-04-2026
- Number Of Sites
- 3
- Number Of Participants
- 11
Sites
- Site Name
- Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
- Department Name
- Oncologie
- Principal Investigator Name
- Tudor Ciuleanu
- Principal Investigator Email
- tudor_ciuleanu@hotmail.com
- Contact Person Name
- Tudor Ciuleanu
- Contact Person Email
- tudor_ciuleanu@hotmail.com
- Site Name
- Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
- Department Name
- Oncologie
- Principal Investigator Name
- Aurelia Alexandru
- Principal Investigator Email
- auralexandru@yahoo.com
- Contact Person Name
- Aurelia Alexandru
- Contact Person Email
- auralexandru@yahoo.com
- Site Name
- Centrul De Oncologie SF Nectarie S.R.L.
- Department Name
- Oncologie
- Principal Investigator Name
- Michael Schenker
- Principal Investigator Email
- mike_schenker@yahoo.com
- Contact Person Name
- Michael Schenker
- Contact Person Email
- mike_schenker@yahoo.com
Spain
- Latest Decision Or Authorization Date
- 03-03-2026
- Number Of Sites
- 10
- Number Of Participants
- 50
Sites
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Oncology
- Principal Investigator Name
- Ignacio Duran Martinez
- Principal Investigator Email
- XXXXX@XXX.com
- Contact Person Name
- Ignacio Duran Martinez
- Contact Person Email
- XXXXX@XXX.com
- Site Name
- Vall D'hebron Institut De Recerca
- Department Name
- Oncology-Genitourinary
- Principal Investigator Name
- Cristina Suarez Rodriguez
- Principal Investigator Email
- csuarez@vhio.net
- Contact Person Name
- Cristina Suarez Rodriguez
- Contact Person Email
- csuarez@vhio.net
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- MEDICAL ONCOLOGY
- Principal Investigator Name
- Miguel Climent Duran
- Principal Investigator Email
- macliment@fivo.org
- Contact Person Name
- Miguel Climent Duran
- Contact Person Email
- macliment@fivo.org
- Site Name
- Hospital General Universitario Reina Sofia
- Department Name
- Oncology
- Principal Investigator Name
- Maria Jose Mendez Vidal
- Principal Investigator Email
- xxxxx@xxx.es
- Contact Person Name
- Maria Jose Mendez Vidal
- Contact Person Email
- xxxxx@xxx.es
- Site Name
- MD Anderson Cancer Center
- Department Name
- Oncology
- Principal Investigator Name
- Enrique Grande Pulido
- Principal Investigator Email
- egrande@mdanderson.es
- Contact Person Name
- Enrique Grande Pulido
- Contact Person Email
- egrande@mdanderson.es
- Site Name
- Complexo Hospitalario Universitario De Santiago
- Department Name
- Oncology
- Principal Investigator Name
- Urbano Anido
- Principal Investigator Email
- urbano.anido.herranz@sergas.es
- Contact Person Name
- Urbano Anido
- Contact Person Email
- urbano.anido.herranz@sergas.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- MEDICAL ONCOLOGY
- Principal Investigator Name
- Begoña Valderrama
- Principal Investigator Email
- xxxxxx@xxx.com
- Contact Person Name
- Begoña Valderrama
- Contact Person Email
- xxxxxx@xxx.com
- Site Name
- Parc Tauli Hospital Universitari
- Department Name
- Oncology
- Principal Investigator Name
- Enrique Gallardo Diaz
- Principal Investigator Email
- egallardo@tauli.cat
- Contact Person Name
- Enrique Gallardo Diaz
- Contact Person Email
- egallardo@tauli.cat
- Site Name
- Hospital Del Mar
- Department Name
- ONCOLOGY
- Principal Investigator Name
- Alejo Rodríguez-Vida Rodríguez
- Principal Investigator Email
- arodriguezvida@parcdesalutmar.cat
- Contact Person Name
- Alejo Rodríguez-Vida Rodríguez
- Contact Person Email
- arodriguezvida@parcdesalutmar.cat
- Site Name
- Universidad De Navarra
- Department Name
- MEDICAL ONCOLOGY
- Principal Investigator Name
- Nuria Lainez Milagro
- Principal Investigator Email
- nuria.lainez.milagro@navarra.es
- Contact Person Name
- Nuria Lainez Milagro
- Contact Person Email
- nuria.lainez.milagro@navarra.es
France
- Latest Decision Or Authorization Date
- 20-04-2026
- Number Of Sites
- 15
- Number Of Participants
- 83
Sites
- Site Name
- Institut De Cancerologie Strasbourg Europe
- Department Name
- Institut de Cancérologie de Strasbourg
- Principal Investigator Name
- Philippe Barthélémy
- Principal Investigator Email
- p.barthelemy@icans.eu
- Contact Person Name
- Philippe Barthélémy
- Contact Person Email
- p.barthelemy@icans.eu
- Site Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Department Name
- Oncologie Médicale
- Principal Investigator Name
- Mathieu Laramas
- Principal Investigator Email
- mlaramas@chu-grenoble.fr
- Contact Person Name
- Mathieu Laramas
- Contact Person Email
- mlaramas@chu-grenoble.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Laurence Albigès
- Principal Investigator Email
- laurence.albiges@gustaveroussy.fr
- Contact Person Name
- Laurence Albigès
- Contact Person Email
- laurence.albiges@gustaveroussy.fr
- Site Name
- Institut Paoli-Calmettes
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Gwenaelle Gravis
- Principal Investigator Email
- gravisg@ipc.unicancer.fr
- Contact Person Name
- Gwenaelle Gravis
- Contact Person Email
- gravisg@ipc.unicancer.fr
- Site Name
- Centre Hospitalier Universitaire D'Angers
- Department Name
- Urologie
- Principal Investigator Name
- Pierre Bigot
- Principal Investigator Email
- pibigot@chu-angers.fr
- Contact Person Name
- Pierre Bigot
- Contact Person Email
- pibigot@chu-angers.fr
- Site Name
- Centre Antoine Lacassagne
- Department Name
- Centre Antoine Lacassagne
- Principal Investigator Name
- Delpine Borchiellini
- Principal Investigator Email
- delphine.borchiellini@nice.unicancer.fr
- Contact Person Name
- Delpine Borchiellini
- Contact Person Email
- delphine.borchiellini@nice.unicancer.fr
- Site Name
- Centre Francois Baclesse
- Department Name
- Centre François Baclesse
- Principal Investigator Name
- Florence Joly
- Principal Investigator Email
- f.joly@baclesse.unicancer.fr
- Contact Person Name
- Florence Joly
- Contact Person Email
- f.joly@baclesse.unicancer.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Institut de Cancérologie de l’Ouest
- Principal Investigator Name
- Frédéric Rolland
- Principal Investigator Email
- frederic.rolland@ico.unicancer.fr
- Contact Person Name
- Frédéric Rolland
- Contact Person Email
- frederic.rolland@ico.unicancer.fr
- Site Name
- Hopital Prive Toulon Hyeres Sainte Marguerite
- Department Name
- Hôpital Privé Toulon Hyeres
- Principal Investigator Name
- Philippe Bernard
- Principal Investigator Email
- philippe.bernard@dartybox.com
- Contact Person Name
- Philippe Bernard
- Contact Person Email
- philippe.bernard@dartybox.com
- Site Name
- Besancon University Hospital Center
- Department Name
- Oncologie Médicale
- Principal Investigator Name
- Hamadi Almotlak
- Principal Investigator Email
- halmotlak@gmail.com
- Contact Person Name
- Hamadi Almotlak
- Contact Person Email
- halmotlak@gmail.com
- Site Name
- Nouvelle Clinique Des Dentellieres
- Department Name
- Centre Les Dentellières
- Principal Investigator Name
- Jessica Grosjean
- Principal Investigator Email
- grosjean@lesdentellieres.com
- Contact Person Name
- Jessica Grosjean
- Contact Person Email
- grosjean@lesdentellieres.com
- Site Name
- Medipole De Nancy
- Department Name
- Centre d'Oncologie de Gentilly
- Principal Investigator Name
- Raafet Affi
- Principal Investigator Email
- r.affi@ilcgroupe.fr
- Contact Person Name
- Raafet Affi
- Contact Person Email
- r.affi@ilcgroupe.fr
- Site Name
- Centre Hospitalier Regional Et Universitaire De Brest
- Department Name
- Oncologie
- Principal Investigator Name
- Emmanuelle Renaud
- Principal Investigator Email
- emmanuelle.renaud@chu-brest.fr
- Contact Person Name
- Emmanuelle Renaud
- Contact Person Email
- emmanuelle.renaud@chu-brest.fr
- Site Name
- Hospital Foch
- Department Name
- Urologie
- Principal Investigator Name
- Thierry Lebret
- Principal Investigator Email
- t.lebret@hopital-foch.org
- Contact Person Name
- Thierry Lebret
- Contact Person Email
- t.lebret@hopital-foch.org
- Site Name
- Les Hopitaux Universitaires De Strasbourg
- Department Name
- Oncologie Médicale
- Principal Investigator Name
- Philippe Barthélémy
- Principal Investigator Email
- p.barthelemy@icans.eu
- Contact Person Name
- Philippe Barthélémy
- Contact Person Email
- p.barthelemy@icans.eu
Poland
- Latest Decision Or Authorization Date
- 21-04-2026
- Number Of Sites
- 5
- Number Of Participants
- 60
Sites
- Site Name
- Copernicus Podmiot Leczniczy Sp. z o.o.
- Principal Investigator Name
- Joanna Wojcik-Tomaszewska
- Principal Investigator Email
- jwojcik@wco.gda.pl
- Contact Person Name
- Joanna Wojcik-Tomaszewska
- Contact Person Email
- jwojcik@wco.gda.pl
- Site Name
- Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy
- Department Name
- Ambulatorium Chemioterapii
- Principal Investigator Name
- Bogdan Żurawski
- Principal Investigator Email
- zurawskib@co.bydgoszcz.pl
- Contact Person Name
- Bogdan Żurawski
- Contact Person Email
- zurawskib@co.bydgoszcz.pl
- Site Name
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Department Name
- Kilinka Nowotworów Układu Moczowego
- Principal Investigator Name
- Paweł Wiechno
- Principal Investigator Email
- wiechno@coi.pl
- Contact Person Name
- Paweł Wiechno
- Contact Person Email
- wiechno@coi.pl
- Site Name
- Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej
- Principal Investigator Name
- Piotr Centkowski
- Principal Investigator Email
- piotr.centkowski@szpitalbp.pl
- Contact Person Name
- Piotr Centkowski
- Contact Person Email
- piotr.centkowski@szpitalbp.pl
- Site Name
- Uniwersytecki Szpital Kliniczny W Poznaniu
- Department Name
- Klinika Onkologii, Oddział Chemioterapii
- Principal Investigator Name
- Piotr Tomczak
- Principal Investigator Email
- md.piotr.tomczak@gmail.com
- Contact Person Name
- Piotr Tomczak
- Contact Person Email
- md.piotr.tomczak@gmail.com
Sponsor
Primary sponsor
- Full Name
- Bristol-Myers Squibb Services Unlimited Company
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Ireland
Contract research organisations
- Name
- Signant Health Global LLC
- Responsibilities
- Subject Number assignment, Treatment/Arm assignment,Drug (re)supplies assignment, IVRS30 – treatment randomisation
- Name
- Accenture Solutions Private Limited
- Responsibilities
- Pharmacovigilance duties: Medical review and Cases Data Entry; Embarc operations (multiple entries)
- Name
- Greenphire LLC
- Responsibilities
- Provides electronic payments, travel arrangements,electronic study-related comunications to patients
- Name
- Icon Laboratory Services Inc.
- Responsibilities
- Data entry of Local Laboratory Values
Third parties
- {"country":"United States","full_name":"Signant Health Global LLC","duties_or_roles":"Subject Number assignment, Treatment/Arm assignment,Drug (re)supplies assignment, IVRS30 – treatment randomisation","organisation_type":"Pharmaceutical company"}
- {"country":"India","full_name":"Accenture Solutions Private Limited","duties_or_roles":"Pharmacovigilance duties: Medical review and Cases Data Entry","organisation_type":"Pharmaceutical company"}
- {"country":"India","full_name":"Accenture Solutions Private Limited","duties_or_roles":"(no duty description provided for this entry)","organisation_type":"Pharmaceutical company"}
- {"country":"India","full_name":"Accenture Solutions Private Limited","duties_or_roles":"Pharmacovigilance duties: Medical review and Cases Data Entry","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"Provides electronic payments, travel arrangements,electronic study-related comunications to patients","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Icon Laboratory Services Inc.","duties_or_roles":"Data entry of Local Laboratory Values","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"India","full_name":"Accenture Solutions Private Limited","duties_or_roles":"Embarc operations","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- OPDIVO 10 mg/mL concentrate for solution for infusion.
- Active Substance
- NIVOLUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- Authorised (marketing authorisation EU/1/15/1014/002)
- Maximum Dose
- 480 mg (max daily dose amount as listed)
- Investigational Product Name
- Ipilimumab
- Active Substance
- IPILIMUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Maximum Dose
- 1 mg/kg (max daily), 4 mg/kg (max total) as listed
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- VOLRUSTOMIG for Advanced renal cell carcinoma
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer